Aim: Arctigenin, a phenylpropanoid dibenzylbutyrolactone lignan found in traditional Chinese herbs, has been determined to exhibit a variety of pharmacological activities, including anti-tumor, anti-inflammation, neuroprotection, and endurance enhancement. In the present study, we investigated the antioxidation and anti-fatigue effects of arctigenin in rats. Methods: Rat L6 skeletal muscle cell line was exposed to H 2 O 2 (700 μmol/L), and ROS level was assayed using DCFH-DA as a probe. Male SD rats were injected with arctigenin (15 mg·kg
Introduction
Normal muscle contraction relies on the redox state of cells in the muscle [1, 2] , and reactive oxygen species (ROS) generated by strenuous exercise can influence the contractile function of skeletal muscles and accelerate fatigue [3] . In addition, muscle fatigue also decreases mobility and quality of life for people with heart failure, cancer cachexia, sarcopenia and catabolic diseases [4] . Moreover, excessive ROS production and accumulation can even damage biomembranes [5] , proteins [6] , and DNA [7] , thereby initiating asthma, chronic obstructive pulmonary disease (COPD) [8] , atherosclerosis, inflammatory diseases [9] , and Parkinson's disease [10] . Therefore, increasing the antioxidant capacity of skeletal muscles can be beneficial for muscle performance, disease prevention and life-quality improvement.
AMP-activated protein kinase (AMPK) is an axis of energy metabolism. It is highly involved in the regulation of glucose uptake, fatty acid oxidation and mitochondrial biogenesis. AMPK activation is helpful to enhance endurance [11] . It has been reported that AMPK activation facilitates ROS reduction [12] . When exercising, the ROS that is produced by the mitochondrial respiratory chain accumulates in skeletal muscles, causing fatigue and increasing the oxidative damage to cells [13] . AMPK activation can prevent cells from overproducing and accumulating ROS in mitochondria [14] , which has www.chinaphar.com Wu RM et al Acta Pharmacologica Sinica npg been recently confirmed by a study on Cordyceps sinensis that elevated the exercise endurance capacity of rats via an increase in the expression of AMPK and its downstream antioxidant genes [15] . Arctigenin ( Figure 1A ), a phenylpropanoid dibenzylbutyrolactone lignan, was isolated from the traditional Chinese herbs Arctium lappa L (burdock), Saussurea medusa (snow lotus) and Forsythia intermedia (border forsythia) [12] . Arctigenin was reported to possess important pharmacological properties, including anti-tumor, anti-inflammation, immunomodulation, neuroprotection, anti-virus, ER stress regulation, and endurance enhancement [12, [16] [17] [18] [19] . For example, arctigenin exhibits anti-inflammatory effects by inhibiting the exudation and recruitment of leukocytes into inflamed tissues via reducing the release/production of inflammatory mediators and also exhibits neuroprotective activity through reducing surplus ROS production and downregulating the mitochondrial membrane potential [20, 21] . Additionally, arctigenin has therapeutic efficacy in experimental models of influenza virus and Japanese encephalitis (JE) [12] . Chronic oral administration of arctigenin can lower blood glucose and improve lipid metabolism in ob/ob mice [22] . Moreover, a previous study in our lab also proved that arctigenin can promote AMPK phosphorylation through CaMKK and LKB1-dependent pathways and improve mouse endurance by enhancing mitochondrial biogenesis and fatty acid synthesis and oxidation [23] . In the present study, we reported that arctigenin could also upregulate antioxidant-related genes to reduce ROS accumulation and production through phosphorylating AMPK, thereby enhancing rat swimming endurance.
Materials and methods

Materials
Dulbecco's modified Eagle's medium (DMEM), fetal bovine and horse serums were purchased from Invitrogen (Carlsbad, CA, USA). Compound C {6-[4-(2-piperidin-1-ylethoxy) phenyl]-3-pyridin-4-ylpyrazolo [1,5-a] pyrimidine, AMPK inhibitor [24] } was obtained from Sigma (St Louis, MO, USA). The protease inhibitor cocktail (AEBSF, 104 mmol/L; aprotinin, 80 μmol/L; bestatin, 4 mmol/L; E-64, 1.4 mmol/L; leupeptin, 2 mmol/L; pepstatin A, 1.5 mmol/L) was obtained from Sigma-Aldrich (St Louis, MO, USA). The BCA protein assay kit was obtained from Pierce (Rockford, IL, USA). The Reactive Oxygen Species Assay Kit, pifithrin-α, ATP Assay Kit, Immunol Fluorescence Staining Kit and Nuclear and Cytoplasmic Protein Extraction Kit were obtained from Beyotime (Haimen, China). RNAiso, RT reagent Kit and SYBR Premix Ex Taq were purchased from TaKaRa (Dalian, China). Anti-AMPK, anti-phospho-AMPK (Thr172), anti-p53, antiLamin A, and anti-phospho-p53 (Ser15) were from Cell Signaling Technology, Inc (Beverly, MA, USA). Nuclear transcription factor erythroid-2-related factor 2 (Nrf2), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), and Cu-Zn superoxide dismutase (Cu,Zn-SOD) antibodies were purchased from Abcam (Cambridge, MA, USA). Secondary antibodies conjugated with horseradish peroxidase IgG (rabbit and mouse) were from Jackson-Immuno Research, and L6 cells (rat skeletal muscle myoblasts) were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). Arctigenin was isolated from the roots of Arctium lappa L, and the purity of arctigenin was determined to be 99% [25] .
Cell culture and differentiation Rat L6 skeletal muscle cell line was cultured in DMEM supplemented with fetal bovine serum (FBS, 10%) with penicillin (100 IU/mL) and streptomycin (100 μg/mL), and grown at 37 °C in an environment of 5% CO 2. To induce myotube differentiation, the cells were cultured in DMEM with 2% horse serum after 100% confluence in a 6-well plate. After being transferred to nitrocellulose membranes, the proteins were blocked for one hour at room temperature with 5% skim milk and then incubated overnight at 4 °C with the primary antibodies. Membranes were washed for 15 min three times with wash buffer (TBST) at room temperature and incubated in TBST buffer (5% milk) for 2 h with horseradish peroxidase (HRP)-conjugated secondary antibodies (anti-rabbit IgG or anti-mouse IgG). Finally, the membranes were washed three times by TBST for 15 min each, and a SuperSignal West Dura chemiluminescence kit (Pierce Biotechnology) was used to reveal the band. The image was captured by an Image Quant LAS 4000 mini (GE, Healthcare).
RT-PCR and quantitative real-time PCR
Total mRNA was isolated from cells and rat skeletal muscles using RNAiso reagent in accordance with the kit instructions. The purity and quantity of the total RNA was measured by OD 260/280 . A 1 μg sample of total RNA was reverse-transcribed with a PrimeScript ® RT Master Mix Perfect Real Time kit (TaKaRa). Quantitative real-time PCR was performed in 96-well plates using SYBR Premix Ex Taq on a DNA Engene Opticon TM2 system (MJ Research, Waltham, MA, USA). The primers are listed in Table 1 .
Immunohistochemistry (IHC-FR)
Gastrocnemius and quadriceps were collected and embedded in OCT cryostat sectioning medium and stored at -80 °C until ready for sectioning. The frozen tissue block was transferred to a cryotome cryostat (-20 °C) prior to sectioning and then cut to the desired thickness (5 µm) using a cryotome. The tissue sections were placed onto glass slides suitable for immunohistochemistry and dried overnight at room temperature. The slides were fixed with pre-cooled acetone for 10 min at room temperature and rinsed 3 times in PBS. The immunofluorescence staining was conducted following the instructions of the appropriate kit. The color of the antibody staining in the tissue sections was observed using a light microscope (OLYM-PUS ix71). Fluorescence staining burdens were counted on every five fields throughout the entire gastrocnemius and quadriceps (8 rats per group) by Image-Pro Plus 6.0 software. Total number of fluorescence-stained plaques in the gastrocnemius and quadriceps (8 rats per group) was calculated for statistical analysis. Sprague-Dawley (SD) male rats at 7 weeks of age were purchased from the Shanghai Experimental Animal Center, Chinese Academy of Sciences, and acclimated to the IVC housing conditions for 2 d before any experimental intervention. Rats were accommodated under standard conditions (strict 12 h light/dark cycle, 22 °C, 60% humidity) and provided with water and food ad libitum.
Animal experiments
A weight-loaded forced swimming test (WFST) was used to evaluate the rats' endurance and performed as described previously [26] with minor modifications. There were 40 SD male rats in the first fatigue test at week 0. In the fatigue test, rats swam in water loaded with 3% of their body weight. The tem- 
Statistical analysis
All data are reported as the mean±standard error of the mean (SEM). Data were analyzed using either a one-way ANOVA with an appropriate post hoc test for comparison of multiple groups or an unpaired Student's t-test for comparison of two groups, as described in the figure legends (GraphPad Prism 5.0 software). A P value of <0.05 was considered to be statistically significant.
Results
Arctigenin decreased ROS in L6 cells
Given that ROS accumulation is tightly linked with the function of skeletal muscles and that arctigenin is effective in enhancing mitochondrial biogenesis and fatty acid oxidation [13, 23] , the potential effect of arctigenin on ROS accumulation was examined. In the assay, L6 cells, which have been widely used in the skeletal muscle endurance or fatigue studies [27, 28] , were differentiated in DMEM with 2% horse serum, and then the ROS level in the cell line induced by H 2 O 2 treatment was detected with the cell-permeable fluorogenic probe DCFH-DA. As shown in Figure 1B , arctigenin dosedependently reduced ROS compared with the DMSO-treated (negative control) group in L6 cells.
Arctigenin increased AMPK phosphorylation and regulated its downstream antioxidant-related pathways in L6 cells
Arctigenin increased AMPK phosphorylation in L6 cells
AMPK is an important checkpoint to maintain energy balance in both cells and organisms [29] and is implicated in ROS reduction [12] . In our previous study, arctigenin was discovered to promote AMPK phosphorylation in mouse myoblast cells (C2C12 cells) [23] . Here, the effect of arctigenin on AMPK phosphorylation in L6 cells was also detected. As shown in Figure  2A , arctigenin dose-dependently increased AMPK phosphorylation in L6 cells similar to its effect on C2C12 cells.
Arctigenin upregulated antioxidant-related gene transcription involving AMPK/p53/Nrf2 pathway
Given that AMPK activation promoted p53 activity through phosphorylating Ser-15, followed by the regulation of glutathione peroxidase (GPX1) [30] and p21 [31] expression levels, we next detected the potential regulation of arctigenin against the phosphorylation of p53 and mRNA level of p21 in L6 cells.
Compared with the DMSO-treated group, arctigenin dosedependently increased p53 phosphorylation and p21 expression in the cells (Figure 2B and 2D) .
As reported, Nrf2 upregulates the gene expression of antioxidant enzymes or proteins, including Cu,Zn-SOD, thioredoxin (Txn) and glutathione reductase (Gsr) through binding to the antioxidant-responsive element (ARE) [32] [33] [34] [35] . p21 can stabilize Nrf2 from degradation and increase the translocation of Nrf2 to the nucleus [36] . With these facts, we next examined the levels of Nrf2 in the nucleus (N) and cytoplasm (C). As indicated in Figure 2C , arctigenin dose-dependently increased Nrf2 in both the nucleus (N) and cytoplasm (C). Additionally, the mRNA levels of antioxidant genes regulated by Nrf2 and p53, such as Cu,Zn-SOD, GPX1, Txn and Gsr, were also investigated after treatment with arctigenin. As shown in Figure 2D , arctigenin obviously elevated the expression of these genes.
Arctigenin was involved in the regulation of AMPK/PGC-1α/ peroxisome proliferator activated receptor α (PPARα) pathway
As a downstream factor of AMPK, PGC-1α activation promotes the expression of antioxidant-related genes (eg, Cu,Zn-SOD and GPX-1) and nuclear receptor PPARα [37] , which can regulate uncoupling protein2 (UCP2) production in mitochondria [37] [38] [39] [40] . Given that arctigenin could induce AMPK activation and upregulate PGC-1α gene expression in skeletal muscles [23] , the activity of arctigenin with respect to PGC-1α, PPARα and related antioxidant genes of UCP2, Cu,Zn-SOD and GPX-1 was investigated next. As expected, arctigenin dose-depend- Figure 2D ). In addition, by considering that UCP2 uncouples ATP synthesis from the oxidative phosphorylation pathway [41] , the level of ATP was also examined after arctigenin incubation. As shown in Figure 2E , arctigenin could dose-dependently increase ATP levels in L6 cells.
Taken together, our results suggested that arctigenin can increase AMPK phosphorylation and upregulate its downstream antioxidant-related enzymes and proteins involving the regulation of AMPK/PGC-1α/PPARα and AMPK/p53/ Nrf2 pathways in L6 cells.
Regulation of arctigenin against antioxidant-related pathways was dependent on AMPK activation
To further investigate whether arctigenin increased p53 phosphorylation, stabilized Nrf2 and upregulated antioxidantrelated genes through AMPK activation, we next evaluated the activity of arctigenin against these genes and proteins together with an AMPK inhibitor (compound C) or p53 inhibitor (pifithrin-α, PFT) in L6 cells. As indicated in Figure 3A -B and D, treatment with compound C inhibited the arctigenininduced p53 phosphorylation and Nrf2 accumulation in the nucleus (N) and cytoplasm (C), as well as the related gene expression in L6 cells. In Figure 3C and E, treatment of PFT inhibited Nrf2 accumulation in the nucleus (N) and cytoplasm (C) and decreased the expression of the p53 target gene p21 and related genes in L6 cells. Therefore, the above-mentioned results imply that the regulation of arctigenin against p53 phosphorylation, Nrf2 and antioxidant-related genes are dependent on AMPK activation.
Arctigenin efficiently enhanced the swimming endurance of sedentary SD rats Given that improvement of skeletal muscle antioxidant capacity is beneficial for muscle performance [4] and that arctigenin has been determined to be effective in reducing ROS levels, we next investigated the potential ability of this natural product to enhance rat endurance as measured by a weight-loaded forced swimming test (WFST) [12] . In the assay, before arctigenin administration, the swimming performance of all SD rats loaded with 3% of their body weight was recorded, and the rats with a swimming exhaustive time beyond the average were eliminated. After 6-week administration (10 and 15 mg/kg) of arctigenin via intraperitoneal injection, the swimming time until fatigue under a similar load was estimated as the maximal endurance capacity. As shown in Figure S1 , arctigenin administration at 10 mg/kg increased the fatigue time by 24.97% (P=0.11) compared with vehicle, but without significance. However, arctigenin administration at 15 
Arctigenin regulated downstream antioxidant-related pathways of AMPK in vivo
To further investigate the underlying mechanism of arctigenin in the improvement of the swimming endurance of sedentary rats, the relevant tissue-based assays were carried out. As expected, arctigenin administration obviously enhanced the phosphorylation of AMPK and p53 and the protein level of Nrf2 in both the gastrocnemius ( Figure 4B ) and quadriceps ( Figure 4C ) as measured by Western blot assays. A qRT-PCR assay demonstrated that arctigenin also upregulated the mRNA levels of PGC-1α, PPARα and UCP2 in the gastrocnemius and quadriceps ( Figure 4F and 4G) . As shown in Figure 4F and 4G regarding the arctigenin group, the mRNA levels of Cu,Zn-SOD and p21 were elevated in the gastrocnemius, and there was a tendency towards increases in GPX1, Gsr, and Txn mRNA levels in the gastrocnemius and quadriceps, but without significance, and in the quadriceps, there was also a tendency towards increases in Cu,Zn-SOD and p21 mRNA levels although without significance. Similarly, the immunohistochemical results in both the gastrocnemius ( Figure 4H ) and quadriceps ( Figure 4I ) also suggested that arctigenin enhanced the levels of Nrf2, Cu,Zn-SOD and PGC-1α. Therefore, all in vivo results further support the potential of arctigenin in ROS elimination. Moreover, the effect of arctigenin on ATP levels was also examined, and the levels of ATP in both gastrocnemius ( Figure 4D ) and quadriceps ( Figure 4E ) were determined to be elevated in the arctigenin treatment group.
Discussion
ROS is a class of endogenous signaling molecule with specific functions depending on its subcellular localization, local concentration and duration of production [42] . A moderate level of ROS transiently oxidizes the cysteine sulphydryl that contributes to the active sites of most proteins [43] and regulates a list of proteins, including tyrosine and serine/threonine www.nature.com/aps Wu RM et al Acta Pharmacologica Sinica npg phosphatases [44, 45] , transcription factors [46, 47] and protease inhibitors [48, 49] . When ROS accumulates to a certain level, its active effects might convert to inhibitory effects that damage cellular functions [50] . Oxidative stress will occur when the production of ROS exceeds its catabolism. Under oxidative stress, ROS may initiate the production of toxic compounds, thereby causing apoptosis [42] . Therefore, discovery of an efficient reagent that is able to reduce ROS is valuable in the treatment of related diseases.
AMPK as an axis of energy metabolism is highly involved in the regulation of the overproduction and accumulation of ROS in mitochondria [14] . AMPK activation upregulates the expression of PGC-1α or directly phosphorylates PGC-1α in skeletal muscles [23] , which subsequently increases the expression of the antioxidant enzymes responsible for ROS reduction, such as Cu,Zn-SOD and GPX1 [51, 52] . UCP2 is one target gene of PPARα and is also regulated by PGC-1α activation [38, 39] . UCP2 has been determined to play a critical role in the control of mitochondrial ROS production [53] . As a mitochondrial anion transporter, UCP2 uncouples ATP synthesis from the oxidative phosphorylation pathway by causing proton leakage across the mitochondrial inner membrane, finally reducing mitochondrial ROS production [53, 54] . In addition, AMPK-induced ROS reduction also involves a series of pathways. For example, AMPK activates p53 through phosphorylating Ser-15 and subsequently affects the expressions of GPX1 [30] and p21 (p53 target gene) [31, 55] . Given that p21 stabilizes Nrf2 by interacting with Kelch-like ECH-associated protein 1 (Keap1) to block Nrf2 degradation in cytosol [36] , p21 stimulation may regulate the expression of the antioxidant enzymes or proteins, such as Cu,Zn-SOD, Txn and Gsr, through enhancing Nrf2 levels in the nucleus to bind the antioxidant-responsive element (B, C) Protein levels of phospho-AMPK, total-AMPK, phospho-p53, total-p53, and Nrf2 were determined by Western blotting in gastrocnemius (B) and quadriceps (C) (n=4/group). (D, E) The levels of ATP were determined in gastrocnemius (D) and quadriceps (E) (n=5/group). (F, G) The expression levels of Cu,Zn-SOD, Txn, Gsr, GPX1, UCP2, p21, PPARα, and PGC-1α from gastrocnemius (F) and quadriceps (G) were measured by qRT-PCR (n=5/group). GAPDH RNA was used as an internal control for calculating mRNA fold changes.
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In the current work, we reported that arctigenin efficiently the enhanced swimming endurance of sedentary SD rats by improving the antioxidant capacity of the skeletal muscles through two antioxidant pathways: AMPK/PGC-1α/PPARα in mitochondria and AMPK/p53/Nrf2 in the cell nucleus. In the regulation of the AMPK/PGC-1α/PPARα pathway, arctigenin-stimulated AMPK activated PGC-1α and increased the expression of its downstream antioxidant-related genes (eg, Cu,Zn-SOD, GPX1). Additionally, PGC-1α activation also regulated PPARα expression, resulting in the elevation of its target gene UCP2. In AMPK/p53/Nrf2 signaling regulation, arctigenin-induced AMPK activation stimulated p53, thus directly promoting the expression of the antioxidant-related gene GPX1. Moreover, it was found that p53 activation also promoted the stabilizing factors Nrf2 and p21, leading to Nrf2 accumulation in both the cell nucleus and cytoplasm and the upregulation of the antioxidant-related genes Cu,Zn-SOD, Txn, and Gsr. Given that the localization of Nrf2 in the nucleus is essential for its function in the regulation of antioxidant gene expression [56] [57] [58] and arctigenin has been determined to accelerate Nrf2 accumulation both in cell nucleus and cytoplasm, the capability of arctigenin to increase the Nrf2 in the nucleus is suggested to be attributed to upregulation of the antioxidantrelated genes. Therefore, all these results have highlighted the potential of arctigenin to inhibit ROS production and accelerate ROS catabolism. Recently, arctigenin was reported to be effective in neuron protection via increasing SOD expression to degrade ROS [12] and exert its anti-inflammatory effect by inhibiting the production of ROS in RAW264.7 cells [59] . Here, we discovered that arctigenin not only stimulated the expression of the key antioxidant-related genes of Cu,Zn-SOD, Txn, Gsr, and GPX1 to degrade ROS but also induced UCP2 expression to inhibit ROS production in skeletal muscles. Our results have thereby expanded the pharmacological functions of arctigenin. Notably, AMPK activator, like AICAR, can mimic exercise without additional training to enhance endurance in sedentary mice, and so does arctigenin in sedentary mice [23, 60] . In our current work, we investigated whether arctigenin could mimic exercise to efficiently enhance the swimming endurance of sedentary rats by the upregulation of antioxidant related pathway, although further investigation is needed to underst A previous study in our lab reported that arctigenin could enhance mouse endurance by promoting AMPK phosphorylation and increasing mitochondrial biogenesis [23] . However, there are seemingly contradictory results in that arctigenin could inhibit mitochondrial respiratory chain complex I and reduce the ratio of AMP/ATP in L6 cells [22, 61] . Actually, the effect of arctigenin on the ratio of AMP/ATP was only tested after 2 h incubation, while the arctigenin-enhanced mouse or rat endurance was a long-term effect with 24 h incubation in cells and a 6-week administration in a mouse or rat model. Therefore, to clarify the relationship between the arctigeninmediated endurance enhancement and mitochondria function, the levels of ATP in L6 cells with long-term incubation and in skeletal muscle, including gastrocnemius and quadriceps, were examined. As shown in Figures 2E and 4D-4E , arctigenin obviously increased ATP levels in the related cells and tissues. Furthermore, the levels of ERRα and cytochrome c responsible for mitochondrial biogenesis in L6 cells, gastrocnemius and quadriceps ( Figure S2 ) were also significantly elevated with arctigenin treatment, similar to the reported results [23] . These results therefore indicated that arctigenin upregulated ATP in rat skeletal muscle via increasing mitochondrial biogenesis to enhance the endurance. Therefore, the effect of arctigenin on endurance enhancement might be due to its functions in mitochondrial biogenesis and antioxidant capacity. Additionally, fatigue has also been reported to be linked to disturbed cerebral dopaminergic neurotransmission, in that an increase in serotonin can inhibit cerebral dopamine neurotransmission to induce fatigue [62] , while improvement of dopamine transmission in the brain can increase the motivation and ability to exercise [63] . It was recently found that arctigenin could improve the movement behaviors and upregulate dopamine levels in mouse brains [20] , which might also contribute to the effect of this natural product on fatigue, although further investigation is needed.
In summary, we demonstrated that arctigenin efficiently enhanced the swimming endurance of sedentary SD rats by elevating the antioxidant capacity of the skeletal muscles through regulation of two antioxidant pathways: AMPK/ PGC-1α/PPARα in mitochondria and AMPK/p53/Nrf2 in the cell nucleus. Our results have revealed the potential of arctigenin in antioxidant and anti-fatigue research to treat related diseases. 
